MedTrace Logo

Maternal and Fetal Outcome With Metformin Therapy for Obese Pregnant Women .

NCT05554679 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 178

Last updated 2024-02-13

No results posted yet for this study

Summary

To evaluate the role of metformin in pregnant women with obesity (BMI above 30) , on maternal and infant outcome.

Conditions

  • Metformin for Obese Pregnant Women

Interventions

DRUG

Metformin

Metformin is an oral insulin-sensitising medication that acts to decrease blood glucose concentrations. It inhibits pathways in the liver that stimulate glucose production and also acts to increase glucose uptake into skeletal muscle and fat cells . Metformin is commonly used in the treatment of type 2 diabetes mellitus and polycystic ovarian syndrome , and is being used increasingly in the treatment of gestational diabetes, having been shown to result in decreased rates of neonatal hypoglycaemia and no increased risk of adverse maternal outcomes when compared with insulin.

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Ahmed Abuelhasan · Assiut University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
17 Years
Max Age
44 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-01
Primary Completion
2022-12-30
Completion
2023-07-11

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05554679 on ClinicalTrials.gov